A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Subjects With Advanced Solid and Hematologic Cancers

CLINICALTRIALS.GOV IDENTIFIER	RECRUITMENT STATUS	FIRST POSTED	LAST UPDATE POSTED
NCT03783403	RECRUITING	DECEMBER 21, 2018	OCTOBER 2, 2020

STUDY DESCRIPTION

Brief Summary

Study CC-95251-ST-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Parts B and C), first-in-human clinical study of CC-95251 in subjects with advanced cancers.

Condition or Disease: Neoplasms

Intervention/treatment: Drug: CC-95251
Drug: Rituximab
Drug: Cetuximab

Phase: Phase 1

DETAILED DESCRIPTION

Study CC-95251-ST-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B & Part C), first-in-human clinical study of CC-95251 in subjects with advanced solid & hematologic cancers. The dose escalation part (Part A) of the study will be conducted in three stages. Stage 1 will evaluate the safety and tolerability of escalating doses of CC-95251, administered IV, to determine the maximum tolerated dose (MTD), non-tolerated dose (NTD), and/or recommended Phase 2 dose (RP2D) of CC-95251. Stage 2 will evaluate the safety and tolerability of escalating doses of CC-95251 in combination with weekly cetuximab, both administered IV, to determine the MTD, NTD, and/or RP2D of CC-95251 plus cetuximab. Stage 3 will evaluate the safety and tolerability of escalating doses of CC-95251 in combination with rituximab, both administered IV, to establish MTD, NTD, and/or RP2D of CC-95251 plus rituximab.

STUDY DESIGN

Study Type: Interventional

Estimated Enrollment : 230 participants

Intervention Model : Single Group Assignment

Masking: None (Open Label) ()

Primary Purpose: Treatment

Official Title: A Phase 1, Open-Label, Dose Finding Study of CC-95251, A Monoclonal Antibody Directed Against SIRPa, Alone and in Combination With Cetuximab or Rituximab in Subjects With Advanced Solid and Hematologic Cancers

Actual Study Start Date: February 2019

Estimated Primary Completion Date: December 2022

Estimated Study Completion Date: December 2024

ARMS AND INTERVENTIONS

Arm	Intervention/treatment
Experimental: CC-95251 alone CC-95251 administered by IV (intravenous) infusion	Drug: CC-95251 CC-95251 administered by IV (intravenous) infusion.
Experimental: CC-95251 in combination with cetuximab CC-95251 administered by IV (intravenous) infusion; Cetuximab administered by IV (intravenous) infusion.	Drug: CC-95251 CC-95251 administered by IV (intravenous) infusion. Drug: Cetuximab Cetuximab administered by IV (intravenous) infusion.
Experimental: CC-95251 in combination with rituximab CC-95251 administered by IV (intravenous) infusion; Rituximab administered by IV (intravenous) infusion.	Drug: CC-95251 CC-95251 administered by IV (intravenous) infusion. Drug: Rituximab Rituximab administered by IV (intravenous) infusion.

OUTCOME MEASURES

Primary Outcome Measures: 1. Adverse Event(s) [Time Frame: From enrollment until at least 56 days after completion of study treatment]
Number of subjects with adverse event

2. Non-Tolerated Dose (NTD) [Time Frame: 18 months]
A dose that causes unacceptable side effects.
3. Maximum Tolerated Dose (MTD) [Time Frame: 18 months]
The highest dose that does not cause unacceptable side effects.
4. Dose-Limiting Toxicity (DLT) [Time Frame: 30 months]
Any adverse events meeting the protocol-defined DLT criteria.

Secondary Outcome Measures:

1. Overall response rate (ORR) [Time Frame: 66 Months]
The percent of subjects whose best response is CR or PR.
2. Time to response (TTR) [Time Frame: 66 Months]
Time from the first dose to the first objective tumor response observed for patients who achieved a CR or PR.
3. Duration of response (DOR) [Time Frame: 66 Months]
Time from the first objective tumor response observed for patients who achieved a CR or PR until the first date at progressive disease is objectively documented.
4. Progression free survival (PFS) [Time Frame: 66 Months]
Time from the first dose to the first occurrence of disease progression or death from any cause.
5. Overall survival (OS) [Time Frame: 66 Months]
Time from the first dose to death due to any cause.
6. Pharmacokinetic - Cmax [Time Frame: 36 Months]
Maximum serum concentration of the drug
7. Pharmacokinetic - Cmin [Time Frame: 36 Months]
Minimum serum concentration of the drug.
8. Pharmacokinetic - AUC [Time Frame: 36 Months]
Area under the serum concentration time-curve of the drug.
9. Pharmacokinetic - tmax [Time Frame: 36 Months]
Time to peak (maximum) serum concentration of the drug.
10. Pharmacokinetic - t1/2 [Time Frame: 36 Months]
Terminal half-life of the drug.
11. Pharmacokinetic - CL [Time Frame: 36 Months]
Total body clearance of the drug from the serum.
12. Pharmacokinetic - Vss [Time Frame: 36 Months]
Volume of distribution of the drug at steady state.
13. Anti-CC-95251 antibody (ADA) assessment [Time Frame: 36 Months]
Determine the presence and frequency of anti-drug antibodies of the drug.

ELIGIBILITY CRITERIA

Ages Eligible for Study: 18 Years and older (Adult, Older Adult)

Sexes Eligible for Study: All

Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:
1. Subject must understand and voluntarily sign an informed consent form (ICF).
2. Subject (male or female) is ≥ 18 years of age at the time of signing the ICF.
3. Subject must have progressed on (or not been able to tolerate due to medical comorbidities or unacceptable toxicity) standard anticancer therapy or for whom no other approved conventional therapy exists and have histological or cytological confirmation of advanced unresectable solid tumors.
4. Subject must have at least one site of measurable disease as determined by RECIST v1.1. NHL subjects must have bi-dimensionally measurable disease on cross sectional imaging by CT or MRI as defined by Lugano/IWG criteria.
5. Subject has an ECOG PS of 0 or 1.
6. Subjects must exhibit acceptable hematopoietic, liver, renal, and coagulation function as assessed by laboratory tests.
7. Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
Exclusion Criteria:
1. Subject has received prior investigational therapy directed at CD47 or SIRPα.
2. Subject has cancer with symptomatic central nervous system involvement.
3. Subject is on chronic systemic immunosuppressive therapy or corticosteroids.
4. Subjects with a history of clinically significant cardiac disease within the previous 6 months.
5. Subject had a prior systemic cancer-directed treatments or investigational modalities ≤ 5 half-lives or 4 weeks prior to starting CC-95251, whichever is shorter.
6. Subject had major surgery ≤ 2 weeks prior to starting CC-95251.
7. Subject is a pregnant or lactating female.
8. Subject has known human immunodeficiency virus (HIV) infection.
9. Subject has known chronic, active hepatitis B or C (HBV/HCV) infection.
10. Ongoing treatment with chronic, therapeutic dosing of anti-coagulants.
11. History of autoimmune hemolytic anemia or autoimmune thrombocytopenia.
12. History of concurrent second cancers requiring active, ongoing systemic treatment.
13. For subjects receiving cetuximab, known history of cetuximab intolerance.

CONTACTS AND LOCATIONS

Contacts

Contact:

Locations

United States, Alabama	University of Alabama Birmingham	Birmingham
United States, Arizona	HonorHealth Research Institute	Scottsdale
United States, California	UC Davis Medical Center	Sacramento

United States, Colorado	Rocky Mountain Cancer Centers, LLP [Aurora-COAU]	Aurora
United States, New York	NYU Langone Laura and Isaac Perlmutter Cancer Center	New York
United States, North Carolina	Levine Cancer Institute	Charlotte
United States, Oklahoma	University of Oklahoma Peggy and Charles Stephenson Cancer Center	Oklahoma City
United States, Oregon	Providence Cancer Center/Earle A. Chiles Res. Inst.	Portland
United States, Pennsylvania	University of Pittsburgh Medical Center - Cancer Pavilion	Pittsburgh
United States, Tennessee	Tennessee Oncology	Nashville
United States, Texas	The University of Texas - MD Anderson Cancer Center	Houston
United States, Texas	US Oncology Research	Irving
United States, Texas	South Texas Accelerated Research Therapeutics	San Antonio
United States, Texas	Texas Oncology - San Antonio Medical Center	San Antonio
Australia, New South Wales	Chris O'Brien Lifehouse	Camperdown
Australia, Victoria	Austin Health - Austin Hospital	Heidelberg
Australia, Victoria	Peter MacCallum Cancer Centre	Melbourne
Canada, Alberta	Cross Cancer Institute	Edmonton
Canada, Ontario	Princess Margaret Cancer Centre	Toronto

Sponsors and Collaborators

Celgene

Investigator

Study Director :	Amar Patel, MD	Celgene

MORE INFORMATION

Responsible Party :	Celgene
ClinicalTrials.gov Identifier :	NCT03783403
Other Study ID Numbers :	CC-95251-ST-001, U1111-1224-8251, NCT03816254
First Posted :	December 21, 2018
Last Update Posted :	October 2, 2020
Last Verified :	September 2020
Studies a U.S. FDA-regulated Drug Product:	Yes
Studies a U.S. FDA-regulated Device Product:	No
Keywords provided by Celgene:	*Antibody* *CC-95251* *SIRPα Advanced Solid Cancers* *Advanced Hematologic Cancers*
Additional relevant MeSH terms :	*Hematologic Neoplasms*